{"id":6735,"date":"2020-09-21T16:05:22","date_gmt":"2020-09-21T14:05:22","guid":{"rendered":"https:\/\/www.verduci.it\/?p=6735"},"modified":"2025-11-20T12:42:58","modified_gmt":"2025-11-20T11:42:58","slug":"eculizumab-treatment-in-patients-with-covid-19-preliminary-results-from-real-life-asl-napoli-2-nord-experience","status":"publish","type":"post","link":"https:\/\/www.verduci.it\/en\/eculizumab-treatment-in-patients-with-covid-19-preliminary-results-from-real-life-asl-napoli-2-nord-experience\/","title":{"rendered":"Eculizumab treatment in patients with COVID-19: preliminary results from real-life ASL Napoli 2 Nord experience"},"content":{"rendered":"<p><strong>Authors:<\/strong> F. Diurno, F.G. Numis, G. Porta, F. Cirillo, S. Maddaluno, A. Ragozzino, P. De Negri, C. Di Gennaro, A. Pagano, E. Allegorico, L. Bressy, G. Bosso, A. Ferrara, C. Serra, A. Montisci, M. D&#8217;Amico, S. Schiano Lo Morello, G. Di Costanzo, A.G. Tucci, P. Marchetti, U. Di Vincenzo, I. Sorrentino, A. Casciotta, M. Fusco, C. Buonerba, M. Berretta, M. Ceccarelli, G. Nunnari, Y. Diessa, S. Cicala, G. Facchini<\/p>\n<p><strong>Affiliation:<\/strong> Department of Emergency and Critical Care, ASL Napoli 2 Nord, \u201cS.M. delle Grazie\u201d Hospital, Pozzuoli (NA), Italy.<br \/>\n  <a href=\"mailto:gaetano.facchini@aslnapoli2nord.it\" title=\"Email Gaetano Facchini\" aria-label=\"Email Gaetano Facchini\">gaetano.facchini@aslnapoli2nord.it<\/a>\n<\/p>\n<h2>Objective<\/h2>\n<p><strong>Objective:<\/strong><br \/>\nSARS-CoV-2\u2013related pneumonia (COVID-19) is a global health emergency due to its high morbidity and mortality and the lack of approved specific pharmacological treatments. This case series presents real-life preliminary data on anti-complement C5 therapy with eculizumab in COVID-19 patients admitted to the intensive care unit at ASL Napoli 2 Nord.<\/p>\n<h2>Patients and Methods<\/h2>\n<p><strong>Patients and Methods:<\/strong><br \/>\nThe case series includes patients with confirmed SARS-CoV-2 infection and severe pneumonia or ARDS treated with up to four off-label infusions of eculizumab. All patients also received: enoxaparin 4,000 IU\/day, lopinavir 800 mg\/day + ritonavir 200 mg\/day, hydroxychloroquine 400 mg\/day, ceftriaxone 2 g\/day IV, vitamin C 6 g\/day for 4 days and non-invasive ventilation (NIV).<\/p>\n<h2>Results<\/h2>\n<p><strong>Results:<\/strong><br \/>\nFour ICU COVID-19 patients with severe pneumonia or ARDS were treated with eculizumab. All achieved clinical recovery. Eculizumab induced a significant reduction in inflammatory markers: mean C-reactive protein decreased from 14.6 mg\/dl to 3.5 mg\/dl. The mean disease duration was 12.8 days.<\/p>\n<h2>Conclusions<\/h2>\n<p><strong>Conclusions:<\/strong><br \/>\nEculizumab appears to have important therapeutic potential in severe COVID-19 cases. Our preliminary results support its off-label use pending confirmation from the ongoing SOLID-C19 trial.<\/p>\n<div class=\"vc_btn3-container verduci-button vc_btn3-center\">\n  <a class=\"vc_general vc_btn3 vc_btn3-size-md vc_btn3-shape-rounded vc_btn3-style-modern\" href=\"https:\/\/www.europeanreview.org\/article\/20875\" target=\"_blank\" rel=\"noopener noreferrer\" title=\"Read the full article on Eculizumab treatment in COVID-19 patients\" aria-label=\"Read the full article on Eculizumab treatment in COVID-19 patients\">Discover more<\/a>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Real-life case series of four severe ICU COVID-19 patients treated with eculizumab: all achieved clinical recovery, with marked CRP reduction and a mean disease duration of about 13 days, supporting the potential role of anti-complement C5 therapy in severe cases.<\/p>\n","protected":false},"author":2883,"featured_media":6737,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[894],"tags":[],"class_list":["post-6735","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Eculizumab treatment in severe COVID-19 \u2013 Preliminary real-life data | Verduci Editore<\/title>\n<meta name=\"description\" content=\"Real-life case series on eculizumab therapy in ICU COVID-19 patients at ASL Napoli 2 Nord, showing inflammatory marker reduction and clinical recovery.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.verduci.it\/en\/eculizumab-treatment-in-patients-with-covid-19-preliminary-results-from-real-life-asl-napoli-2-nord-experience\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eculizumab treatment in severe COVID-19 \u2013 Preliminary real-life data | Verduci Editore\" \/>\n<meta property=\"og:description\" content=\"Real-life case series on eculizumab therapy in ICU COVID-19 patients at ASL Napoli 2 Nord, showing inflammatory marker reduction and clinical recovery.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.verduci.it\/en\/eculizumab-treatment-in-patients-with-covid-19-preliminary-results-from-real-life-asl-napoli-2-nord-experience\/\" \/>\n<meta property=\"og:site_name\" content=\"Verduci\" \/>\n<meta property=\"article:published_time\" content=\"2020-09-21T14:05:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-20T11:42:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.verduci.it\/wp-content\/uploads\/2020\/09\/scientist-using-microscope-in-medical-lab-H2MV8DT-min.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1709\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Verduci\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Verduci\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.verduci.it\\\/en\\\/eculizumab-treatment-in-patients-with-covid-19-preliminary-results-from-real-life-asl-napoli-2-nord-experience\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.verduci.it\\\/en\\\/eculizumab-treatment-in-patients-with-covid-19-preliminary-results-from-real-life-asl-napoli-2-nord-experience\\\/\"},\"author\":{\"name\":\"Verduci\",\"@id\":\"https:\\\/\\\/www.verduci.it\\\/#\\\/schema\\\/person\\\/6d04f63706e39a6c3bbd8ad40fadceee\"},\"headline\":\"Eculizumab treatment in patients with COVID-19: preliminary results from real-life ASL Napoli 2 Nord experience\",\"datePublished\":\"2020-09-21T14:05:22+00:00\",\"dateModified\":\"2025-11-20T11:42:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.verduci.it\\\/en\\\/eculizumab-treatment-in-patients-with-covid-19-preliminary-results-from-real-life-asl-napoli-2-nord-experience\\\/\"},\"wordCount\":291,\"publisher\":{\"@id\":\"https:\\\/\\\/www.verduci.it\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.verduci.it\\\/en\\\/eculizumab-treatment-in-patients-with-covid-19-preliminary-results-from-real-life-asl-napoli-2-nord-experience\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.verduci.it\\\/wp-content\\\/uploads\\\/2020\\\/09\\\/scientist-using-microscope-in-medical-lab-H2MV8DT-min.jpg\",\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.verduci.it\\\/en\\\/eculizumab-treatment-in-patients-with-covid-19-preliminary-results-from-real-life-asl-napoli-2-nord-experience\\\/\",\"url\":\"https:\\\/\\\/www.verduci.it\\\/en\\\/eculizumab-treatment-in-patients-with-covid-19-preliminary-results-from-real-life-asl-napoli-2-nord-experience\\\/\",\"name\":\"Eculizumab treatment in severe COVID-19 \u2013 Preliminary real-life data | Verduci Editore\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.verduci.it\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.verduci.it\\\/en\\\/eculizumab-treatment-in-patients-with-covid-19-preliminary-results-from-real-life-asl-napoli-2-nord-experience\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.verduci.it\\\/en\\\/eculizumab-treatment-in-patients-with-covid-19-preliminary-results-from-real-life-asl-napoli-2-nord-experience\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.verduci.it\\\/wp-content\\\/uploads\\\/2020\\\/09\\\/scientist-using-microscope-in-medical-lab-H2MV8DT-min.jpg\",\"datePublished\":\"2020-09-21T14:05:22+00:00\",\"dateModified\":\"2025-11-20T11:42:58+00:00\",\"description\":\"Real-life case series on eculizumab therapy in ICU COVID-19 patients at ASL Napoli 2 Nord, showing inflammatory marker reduction and clinical recovery.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.verduci.it\\\/en\\\/eculizumab-treatment-in-patients-with-covid-19-preliminary-results-from-real-life-asl-napoli-2-nord-experience\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.verduci.it\\\/en\\\/eculizumab-treatment-in-patients-with-covid-19-preliminary-results-from-real-life-asl-napoli-2-nord-experience\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.verduci.it\\\/en\\\/eculizumab-treatment-in-patients-with-covid-19-preliminary-results-from-real-life-asl-napoli-2-nord-experience\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.verduci.it\\\/wp-content\\\/uploads\\\/2020\\\/09\\\/scientist-using-microscope-in-medical-lab-H2MV8DT-min.jpg\",\"contentUrl\":\"https:\\\/\\\/www.verduci.it\\\/wp-content\\\/uploads\\\/2020\\\/09\\\/scientist-using-microscope-in-medical-lab-H2MV8DT-min.jpg\",\"width\":2560,\"height\":1709,\"caption\":\"Researcher in gown and mask examining a sample under a microscope in the laboratory\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.verduci.it\\\/en\\\/eculizumab-treatment-in-patients-with-covid-19-preliminary-results-from-real-life-asl-napoli-2-nord-experience\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.verduci.it\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eculizumab treatment in patients with COVID-19: preliminary results from real-life ASL Napoli 2 Nord experience\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.verduci.it\\\/#website\",\"url\":\"https:\\\/\\\/www.verduci.it\\\/\",\"name\":\"Verduci\",\"description\":\"Editoria Medico Scientifica Internazionale\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.verduci.it\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.verduci.it\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.verduci.it\\\/#organization\",\"name\":\"Verduci Editore s.r.l.\",\"url\":\"https:\\\/\\\/www.verduci.it\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.verduci.it\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.verduci.it\\\/wp-content\\\/uploads\\\/2020\\\/04\\\/verduci-editore-logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.verduci.it\\\/wp-content\\\/uploads\\\/2020\\\/04\\\/verduci-editore-logo.svg\",\"width\":\"1024\",\"height\":\"1024\",\"caption\":\"Verduci Editore s.r.l.\"},\"image\":{\"@id\":\"https:\\\/\\\/www.verduci.it\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.verduci.it\\\/#\\\/schema\\\/person\\\/6d04f63706e39a6c3bbd8ad40fadceee\",\"name\":\"Verduci\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Eculizumab treatment in severe COVID-19 \u2013 Preliminary real-life data | Verduci Editore","description":"Real-life case series on eculizumab therapy in ICU COVID-19 patients at ASL Napoli 2 Nord, showing inflammatory marker reduction and clinical recovery.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.verduci.it\/en\/eculizumab-treatment-in-patients-with-covid-19-preliminary-results-from-real-life-asl-napoli-2-nord-experience\/","og_locale":"en_US","og_type":"article","og_title":"Eculizumab treatment in severe COVID-19 \u2013 Preliminary real-life data | Verduci Editore","og_description":"Real-life case series on eculizumab therapy in ICU COVID-19 patients at ASL Napoli 2 Nord, showing inflammatory marker reduction and clinical recovery.","og_url":"https:\/\/www.verduci.it\/en\/eculizumab-treatment-in-patients-with-covid-19-preliminary-results-from-real-life-asl-napoli-2-nord-experience\/","og_site_name":"Verduci","article_published_time":"2020-09-21T14:05:22+00:00","article_modified_time":"2025-11-20T11:42:58+00:00","og_image":[{"width":2560,"height":1709,"url":"https:\/\/www.verduci.it\/wp-content\/uploads\/2020\/09\/scientist-using-microscope-in-medical-lab-H2MV8DT-min.jpg","type":"image\/jpeg"}],"author":"Verduci","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Verduci","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.verduci.it\/en\/eculizumab-treatment-in-patients-with-covid-19-preliminary-results-from-real-life-asl-napoli-2-nord-experience\/#article","isPartOf":{"@id":"https:\/\/www.verduci.it\/en\/eculizumab-treatment-in-patients-with-covid-19-preliminary-results-from-real-life-asl-napoli-2-nord-experience\/"},"author":{"name":"Verduci","@id":"https:\/\/www.verduci.it\/#\/schema\/person\/6d04f63706e39a6c3bbd8ad40fadceee"},"headline":"Eculizumab treatment in patients with COVID-19: preliminary results from real-life ASL Napoli 2 Nord experience","datePublished":"2020-09-21T14:05:22+00:00","dateModified":"2025-11-20T11:42:58+00:00","mainEntityOfPage":{"@id":"https:\/\/www.verduci.it\/en\/eculizumab-treatment-in-patients-with-covid-19-preliminary-results-from-real-life-asl-napoli-2-nord-experience\/"},"wordCount":291,"publisher":{"@id":"https:\/\/www.verduci.it\/#organization"},"image":{"@id":"https:\/\/www.verduci.it\/en\/eculizumab-treatment-in-patients-with-covid-19-preliminary-results-from-real-life-asl-napoli-2-nord-experience\/#primaryimage"},"thumbnailUrl":"https:\/\/www.verduci.it\/wp-content\/uploads\/2020\/09\/scientist-using-microscope-in-medical-lab-H2MV8DT-min.jpg","articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.verduci.it\/en\/eculizumab-treatment-in-patients-with-covid-19-preliminary-results-from-real-life-asl-napoli-2-nord-experience\/","url":"https:\/\/www.verduci.it\/en\/eculizumab-treatment-in-patients-with-covid-19-preliminary-results-from-real-life-asl-napoli-2-nord-experience\/","name":"Eculizumab treatment in severe COVID-19 \u2013 Preliminary real-life data | Verduci Editore","isPartOf":{"@id":"https:\/\/www.verduci.it\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.verduci.it\/en\/eculizumab-treatment-in-patients-with-covid-19-preliminary-results-from-real-life-asl-napoli-2-nord-experience\/#primaryimage"},"image":{"@id":"https:\/\/www.verduci.it\/en\/eculizumab-treatment-in-patients-with-covid-19-preliminary-results-from-real-life-asl-napoli-2-nord-experience\/#primaryimage"},"thumbnailUrl":"https:\/\/www.verduci.it\/wp-content\/uploads\/2020\/09\/scientist-using-microscope-in-medical-lab-H2MV8DT-min.jpg","datePublished":"2020-09-21T14:05:22+00:00","dateModified":"2025-11-20T11:42:58+00:00","description":"Real-life case series on eculizumab therapy in ICU COVID-19 patients at ASL Napoli 2 Nord, showing inflammatory marker reduction and clinical recovery.","breadcrumb":{"@id":"https:\/\/www.verduci.it\/en\/eculizumab-treatment-in-patients-with-covid-19-preliminary-results-from-real-life-asl-napoli-2-nord-experience\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.verduci.it\/en\/eculizumab-treatment-in-patients-with-covid-19-preliminary-results-from-real-life-asl-napoli-2-nord-experience\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.verduci.it\/en\/eculizumab-treatment-in-patients-with-covid-19-preliminary-results-from-real-life-asl-napoli-2-nord-experience\/#primaryimage","url":"https:\/\/www.verduci.it\/wp-content\/uploads\/2020\/09\/scientist-using-microscope-in-medical-lab-H2MV8DT-min.jpg","contentUrl":"https:\/\/www.verduci.it\/wp-content\/uploads\/2020\/09\/scientist-using-microscope-in-medical-lab-H2MV8DT-min.jpg","width":2560,"height":1709,"caption":"Researcher in gown and mask examining a sample under a microscope in the laboratory"},{"@type":"BreadcrumbList","@id":"https:\/\/www.verduci.it\/en\/eculizumab-treatment-in-patients-with-covid-19-preliminary-results-from-real-life-asl-napoli-2-nord-experience\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.verduci.it\/en\/"},{"@type":"ListItem","position":2,"name":"Eculizumab treatment in patients with COVID-19: preliminary results from real-life ASL Napoli 2 Nord experience"}]},{"@type":"WebSite","@id":"https:\/\/www.verduci.it\/#website","url":"https:\/\/www.verduci.it\/","name":"Verduci","description":"Editoria Medico Scientifica Internazionale","publisher":{"@id":"https:\/\/www.verduci.it\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.verduci.it\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.verduci.it\/#organization","name":"Verduci Editore s.r.l.","url":"https:\/\/www.verduci.it\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.verduci.it\/#\/schema\/logo\/image\/","url":"https:\/\/www.verduci.it\/wp-content\/uploads\/2020\/04\/verduci-editore-logo.svg","contentUrl":"https:\/\/www.verduci.it\/wp-content\/uploads\/2020\/04\/verduci-editore-logo.svg","width":"1024","height":"1024","caption":"Verduci Editore s.r.l."},"image":{"@id":"https:\/\/www.verduci.it\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.verduci.it\/#\/schema\/person\/6d04f63706e39a6c3bbd8ad40fadceee","name":"Verduci"}]}},"_links":{"self":[{"href":"https:\/\/www.verduci.it\/en\/wp-json\/wp\/v2\/posts\/6735","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.verduci.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.verduci.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.verduci.it\/en\/wp-json\/wp\/v2\/users\/2883"}],"replies":[{"embeddable":true,"href":"https:\/\/www.verduci.it\/en\/wp-json\/wp\/v2\/comments?post=6735"}],"version-history":[{"count":3,"href":"https:\/\/www.verduci.it\/en\/wp-json\/wp\/v2\/posts\/6735\/revisions"}],"predecessor-version":[{"id":10623,"href":"https:\/\/www.verduci.it\/en\/wp-json\/wp\/v2\/posts\/6735\/revisions\/10623"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.verduci.it\/en\/wp-json\/wp\/v2\/media\/6737"}],"wp:attachment":[{"href":"https:\/\/www.verduci.it\/en\/wp-json\/wp\/v2\/media?parent=6735"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.verduci.it\/en\/wp-json\/wp\/v2\/categories?post=6735"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.verduci.it\/en\/wp-json\/wp\/v2\/tags?post=6735"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}